Trimethoprim-sulfamethoxazole 480 mg once daily is more effective than cranberry capsules 500 mg twice daily for the prevention of recurrent urinary tract infection in premenopausal women, but it exacerbates the problem of emerging antibiotic resistance.
Trimethoprim-sulfamethoxazole (TMP-SMX) 480 mg once daily is more effective than cranberry capsules 500 mg twice daily for the prevention of recurrent urinary tract infections (UTIs) in premenopausal women-but it exacerbates the problem of emerging antibiotic resistance.
Researchers from the Netherlands conducted a double-blind, noninferiority trial involving 221 women with recurrent UTIs. They randomized the women to receive 12 months of prophylaxis with either TMP-SMX or the cranberry capsules. After 1 year, the mean number of women who had at least 1 symptomatic UTI was higher in the cranberry group than in the TMP-SMX group (4.0 vs 1.8; P=.02). Additionally, the proportion of women with at least 1 symptomatic UTI was higher in the cranberry group than in the TMP-SMX group (78.2% vs 71.1%). Median time to first symptomatic infection was half in the cranberry group of what it was in the antibiotic group (4 months vs 8 months).
However, after 1 month of treatment, although only about one-quarter of fecal (23.7%) and asymptomatic bacteriuria Escherichia coli isolates (28.1%) in the cranberry group were TMP-SMX resistant, 86.3% of fecal and 90.5% of asymptomatic bacteriuria E coli isolates in the antibiotic group were resistant to TMP-SMX. After 1 month, the isolates in the latter group also showed increased resistance rates to trimethoprim, amoxicillin, and ciprofloxacin. Resistance rates returned to baseline 3 months after discontinuation of TMP-SMX.
Beerepoot MA, Ter Riet G, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med. 2011;171(14):1270-1278.
Multicomponent intervention boosts quality of life in overactive bladder patients
March 15th 2024A recent study reveals the efficacy of a cognitive behavior therapy program, showcasing significant improvements in health-related quality of life among women grappling with moderate to severe overactive bladder.
Read More
Optimizing pain management post urogynecologic surgery with restrictive opioid protocol
March 14th 2024A recent study suggests that restrictive opioid prescribing protocols post-urogynecologic surgery are as effective as standard protocols, emphasizing the importance of multimodal analgesia and outpatient follow-up for patient satisfaction.
Read More
Study finds no increased stress urinary incontinence recurrence risk from childbirth
March 11th 2024A recent meta-analysis challenged common clinical assumptions, finding no increased risk of stress urinary incontinence recurrence or need for reoperation after subsequent pregnancy and childbirth following a midurethral sling procedure.
Read More
Cefepime–Taniborbactam outperforms meropenem in treating complicated UTI
February 15th 2024A recent study demonstrated the superior efficacy of cefepime–taniborbactam over meropenem for managing complicated urinary tract infections, suggesting a promising treatment option amid rising antibiotic resistance challenges.
Read More